ReviewReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology2025
Daily iron supplementation for prevention or treatment of moderate iron deficiency anemia in patients with solid neoplasm, undergoing concurrent radiochemotherapy treatment.
Review in Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anemia has a significant clinical impact on cancer patients: it is related to an important decline in performance status (PS) and quality of life (QoL), with progressive worsening of cognitive function and energy-activity levels. Materials and methods: To evaluate the effectiveness of Sucrosomial Results: In arm A, at baseline, the median hemoglobin (Hb) value was 12.4 g/dL. After 15 days, 30 days and 60 days, median Hb values were, respectively, 12.2 g/dL, 11.8 g/dL, and 11.6 g/dL. In arm B, at baseline, the median Hb value was 12.30 g/dL. After 15 days, 30 days and 60 days, Hb values were, respectively, 11.7 g/dL, 11.2 g/dL, and 11.2 g/dL. Regarding the difference in QoL between the two treatment groups, in Arm A a consistent stability in FACT-An questionnaire scores was noted. Conversely, in Arm B, a slow but constant increase in FACT-An scores was observed. Conclusions: Sucrosomial
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.